The data presented in this manuscript suggest that IKKα inhibitors should also be developed and used in combination with IKKβ inhibitors to limit inflammation during bacterial infection or in inflammatory disorders that may involve Nod1 signaling, including asthma, eczema and inflammatory bowel diseases [36], [37], [38]. Here, CHUK is linked to inflammatory bowel disease.